Volume 27, Issue 4 - Patient-reported outcomes

Patient-reported outcome measure translation: An overview

Authors: Cate Talley, Shawn McKown

Abstract

Download the full article

References

1. Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of healthrelated quality of life (HRQL) measures in the evaluation of medicinal products. London, European Medicines Agency. 2005 Jul 27. Available from: http://
2. US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patientreported outcome measures: use in medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes. 2006 Dec;4:1–20. Available from: http://
3. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005 Mar;8(2):94–104. Available from: http://
4. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013 Oct 1;22(8):1889–905. Available from: http://
5. Gawlicki MC, Angun Ç, Brandt BA, McKown S, Schulz C, Talbert M. Localization of activities and equivalence of movements in clinical outcomes Patient-reported outcome measure translation: An overview – Talley and McKown www.emwa.org Volume 27 Number 4 | Medical Writing December 2018 | 29 assessments. Value Health. 2013 Nov 1;16(7):A597. Available from: http://
6. Gawlicki MC, Brandt BA, McKown S, Talbert M. The translatability of fatigue across languages. Presented at the International Society for Quality of Life Research, 21st Annual Conference, Berlin, October 15–18, 2014 (poster). Available from: http://
7. Gawlicki MC, McKown SM, Talbert MJ, Brandt BA. Application of Bother in patient reported outcomes instruments across cultures. Health Qual Life Outcomes. 2014 Dec;12(1):18. Available from: http://
8. McKown S, Angun C, Talbert M, Brandt BA, Gawlicki MC. Assessing the translatability of the term “frustrated”. Value Health. 2014 Nov 1;17(7):A516–7. Available from: http://
9. Talbert M, Brandt B, McKown S, Gawlicki M. Assessing the translatability of the term “distressed”. Value Health. 2015 Nov 1;18(7):A710. Available from: http://
10. Gawlicki MC, Brandt B, McKown S, Talbert M. Translatability of response sets used in patient reported outcomes and best practices for development. Value Health. 2012;7(15):A484. Available from: http://
11. Gawlicki MC, Brandt BA, McKown S, Talbert M. Face Validation and Trans - latability Assessment of Clinical Outcomes Assessments. Presented at the 20th Annual Conference of the International Society for Quality of Life Research, Miami, October 9 - 12, 2013 (poster). Available from: http://
12. Gawlicki MC, Handa M, McKown S. Preempting difficulties in linguistic validation: the use of face validation to create more sound translations. Value Health. 2010;13(7):A336. Available from: http://
13. Acquadro C, Patrick DL, Eremenco S, et al. Emerging good practices for translatability assessment (TA) of patientreported outcome (PRO) measures. J Patient Rep Outcomes. 2017 Dec 1;2(1):8. Available from: http://